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Mastocytosis is a heterogeneous group of diseases defi-
ned by an increased number and accumulation of mast 
cells, and often also by signs and symptoms of mast cell 
activation. Disease subtypes range from indolent to rare 
aggressive forms. Mastocytosis affects people of all ages 
and has been considered rare; however, it is probably 
underdiagnosed with potential severe implications. Di-
agnosis can be challenging and symptoms may be com-
plex and involve multiple organ-systems. In general it 
is advised that patients should be referred to centres 
with experience in the disease offering an individualized, 
multidisciplinary approach. We present here consensus 
recommendations from a Nordic expert group for the di-
agnosis and general management of patients with mas-
tocytosis. Key words: mastocytosis; systemic mastocytosis; 
urticaria pigmentosa; classification; diagnostic criteria; 
mast cell; multidisciplinary management.
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Mastocytosis is a heterogeneous group of diseases cha-
racterized by expansion and accumulation of tissue mast 
cells (MCs) in various organ systems (1, 2). Clinical 
manifestations are caused by MC infiltration and effects 
of mediators released from activated MCs. Mastocytosis 
has been considered rare, but is probably underdiagnosed 
and may affect children as well as adults. 
This document has been prepared in a collaborative 
effort between existing mastocytosis centres in Den-
mark, Sweden, Norway and Finland and has developed 
through discussions at meetings in Stockholm, Vienna, 
Odense and London between 2010 and 2015. Further-
more, to adjust content and recommendations to inter-
nationally accepted guidelines the document has been 
critically revised by a major external discussant, the 
founder and coordinator of the European Competence 
Network on Mastocytosis (ECNM) (PV). Our aim is 
to provide general recommendations for healthcare 
professionals involved in diagnosing and treating pa-
tients with mastocytosis. Given the relative rarity and 
heterogeneity of the disease, which may have severe 
implications, it is generally advised that patients with 
mastocytosis are referred to centres with experience 
in the management and treatment of the disease, i.e. 
a centre of excellence of the ECNM (www.ecnm.net). 
Typically, these centres offer a multidisciplinary, coor-
dinated and tailored approach to the individual patient. 
WHO CLASSIFICATION AND DISEASE SUBTYPES
The WHO classifies mastocytosis into 7 subcategories, 
including cutaneous mastocytosis (CM), where major 
MC accumulations are limited to the skin, and systemic 
mastocytosis (SM), where internal organs are involved 
(2–4) (Table I). In general, most adults (> 95%) with mas-
tocytosis are diagnosed with SM when fully investigated, 
with potential multiple clinical manifestations ranging 
from mild to very severe or even life-threatening (Fig.1).
In affected children, on the other hand, the disease 
manifestations are almost exclusively limited to the skin 
and symptoms are often mild. Whereas adult-onset mas-
tocytosis is a chronic disease, paediatric mastocytosis 
has a tendency to spontaneous remission in approxi-
mately 70–80% of children in the teenage years (5, 6).
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SM is divided into several subtypes, of which indolent 
SM (ISM) by far is the most prevalent (Table I). ISM is 
characterized by a stable or only very slowly progres-
sing, benign course and a life-expectancy not differing 
from the (healthy) background population (7, 8). The 
main challenge in ISM is to control MC mediator-related 
symptoms. Subtypes of ISM include bone marrow mas-
tocytosis (BMM), in which skin lesions are absent; and 
smouldering SM (SSM) where the burden of neoplastic 
MCs is high and clonal multi-lineage involvement is 
present. SSM is defined by the presence of at least 2 
“B-findings” (Table II). Although organomegaly often 
occurs, organ damage is not present (2). In most patients 
with SSM the course remains indolent; however, it is 
advised to monitor patients regularly due to an increased 
risk for progression to advanced SM. Given its distinct 
pathogenesis and prognosis SSM can be regarded as a 
separate category of SM (2, 9).
Mastocytosis in the skin (MIS) denominates patients 
with typical skin lesions in whom a full work-up for SM 
including a bone marrow (BM) investigation has not (yet) 
been performed (2). Most adult patients with MIS are con-
sidered to have ISM if investigated (10). However, there 
are adult patients with true CM, in whom the prognosis 
and organ involvement are different from those with SM. 
Therefore, a BM examination is recommended for all 
adult patients with MIS. In children, on the other hand, 
MIS in general does not lead to examination for SM; and 
in this situation CM is accepted as the final diagnosis (2).
The advanced forms of SM are much rarer than indolent 
forms and they almost exclusively occur in adulthood. 
Aggressive SM (ASM) is characterized by massive MC 
infiltration in organs such as bone marrow, liver and bone, 
resulting in organ damage (referred to as a “C-finding” 
(Table II). The prognosis in ASM is poor, but survival 
times vary depending on several different prognostic va-
riables. One of the most important indicators of advanced 
disease is the percentage of MCs in BM smears. In ASM 
patients in whom the percentage of MCs in the bone mar-
row smears exceeds 5% the prognosis is grave, as many 
of these cases transform to mast cell leukaemia (MCL) 
within a short time. Therefore, these patients (5–19%) 
have been referred to as ASM in transformation (ASM-t) 
(11). As soon as the percentage of MCs in the BM smear 
increases to 20% the diagnosis changes to MCL.
SM-AHNMD is characterized by SM and the presence 
of an associated (concomitant) non-MC-lineage clonal 
haematological disease. The SM component is typically 
ISM or ASM, whereas the AHNMD component of the 
disease most often is a clonal myeloid neoplasm; a myelo-
dysplastic syndrome (MDS), chronic myelomonocytic 
leukaemia (CMML), myeloproliferative disorder or acute 
myeloid leukaemia (AML); whereas lymphoproliferative 
disorders are far less common. The prognosis in SM-
Table I. WHO classification of mastocytosis
Cutaneous mastocytosis (CM)
Indolent systemic mastocytosis (ISM) 
Systemic mastocytosis with associated haematological non-MC-lineage 
disease (SM-AHNMD) 
Aggressive systemic mastocytosis (ASM)
Mast cell leukaemia (MCL)
Mast cell sarcoma (MCS)
Extracutaneous mastocytoma
From Horny et al. (4).
Table II. WHO “B- and C-findings” in systemic mastocytosis
B-findings
Bone marrow biopsy showing >30% infiltration by mast cells (focal, dense aggregates) and serum total tryptase level >200 ng/ml
Signs of dysplasia or myeloproliferation in non-mast cell lineage, but insufficient criteria for definitive diagnosis of a haematopoietic neoplasm 
(associated non-MC-lineage clonal haematological disease; AHNMD), with normal or only slightly abnormal blood counts
Hepatomegaly without impairment of liver function, and/or palpable splenomegaly without hypersplenism, and/or lymphadenopathy on palpation or imaging
C-findings
Bone marrow dysfunction manifested by one or more cytopaenia (absolute neutrophil count < 1.0 × 109/l, Hb < 10 g/dl, or platelets < 100 × 109/l), but no frank 
non-mast cell haemato poietic malignancy
Palpable hepatomegaly with impairment of liver function, ascites and/or portal hypertension
Skeletal involvement with large osteolytic lesions and/or pathological fractures* 
Palpable splenomegaly with hypersplenism
Malabsorption with weight loss due to gastrointestinal mast cell infiltrates
Smouldering systemic mastocytosis (SSM) requires that 2 or more B-findings and no C-findings are present. Aggressive systemic mastocytosis (ASM) 
requires presence of one C-finding and documentation of local mast cell (MC) infiltration. *Should not be confused with osteoporosis and resulting vertebral 
compression fractures, commonly seen in indolent systemic mastocytosis.
From Horny et al. (4).
Fig. 1. Various clinical presentations of mastocytosis.
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pigmentosa 
Flushing, itch, 
wheals 
Abnormal 
hematological 
parameters 
Weight loss, fatigue 
Familial occurence Ascites, 
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Anaphylaxis 
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AHNMD depends both on the type of AHNMD and the 
type of SM and, in general, the treatment strategy is to 
treat the AHNMD- and the SM-part independently ac-
cording to its own treatment guidelines (2, 4). 
MCL is the rarest form of ASM, accounting for less 
than 1% of SM cases. The diagnosis is based on the pre-
sence of  ≥ 20% of pathological MCs in the BM smear. In 
the classical variant, ≥ 10% of all peripheral leukocytes 
are MCs, whereas in the more frequent aleukaemic vari-
ant, MCs in the peripheral blood comprise less than 10% 
of all leukocytes. In general, MCL has a poor prognosis 
with a median survival time of less than one year. MCL 
can, however, be either acute or chronic. The acute form 
of MCL is characterized by the presence of C-findings 
(organ damage) and a rapid, malignant course, whereas 
the chronic form of MCL is defined by the absence of C-
findings; and these patients may remain stable for longer, 
even though most patients with chronic MCL eventually 
transform to acute MCL and succumb to the disease (12). 
The WHO classification further includes MC sarcoma 
and extracutaneous mastocytoma. These disease forms 
are exceptional rarities and will not be discussed further 
in the present article.
EPIDEMIOLOGY
Reports on epidemiological aspects of mastocytosis are 
scarce. In a recent nationwide study in Denmark based 
on Danish health registries an estimated prevalence of 
mastocytosis of all subtypes in adults was found to be 10 
in 100,000 with a slight female predominance (8). In this 
study, indolent disease forms (ISM and CM) comprised 
92%, SM-AHNMD 5%, ASM 2% and MCL less than 
1% of cases, respectively. A similar prevalence of ISM 
was found in a single-centre study from Holland (13).
In general, the disease is highly likely to be underdia-
gnosed due to a lack of awareness among medical care 
providers and due to the very heterogeneous clinical 
presentation. With increasing awareness and new diag-
nostic options the prevalence is anticipated to increase.
The prevalence of paediatric mastocytosis is not 
known, but it is estimated to be higher than that of SM.
PATHOGENESIS
In most patients with SM a somatic gain-of-function 
point mutation in the KIT gene leads to a stem cell 
factor (SCF)-independent constitutive activation and 
autophosphorylation of KIT with subsequent expansion 
of clonal MCs. The cause of MC accumulation in masto-
cytosis apparently involves an upregulated recruitment of 
MCs from their progenitor cells and defective apoptosis 
in mature MCs rather than uncontrolled MC proliferation, 
since increased mitotic activity in neoplastic MCs is rarely 
encountered histologically, and furthermore, in the vast 
majority of patients, the disease follows a benign course. 
By far the most frequent KIT mutation in SM involves 
codon 816, resulting in the replacement of an aspartic acid 
by a valine residue (D816V) that is critically involved in 
the kinase activity of KIT. Using highly sensitive methods 
this KIT D816V mutation can be detected in more than 
90% of adults with mastocytosis, not only in lesional 
mast cells from the skin and bone marrow, but often also 
in circulating leukocytes in the peripheral blood (14–17). 
The pathogenesis of paediatric mastocytosis is less well 
understood. As opposed to adult patients the KIT D816V 
mutation can be detected in only approximately 25–35% 
of affected children (6). KIT mutations in codons other 
than 816 are relatively more prevalent in the paediatric 
population compared with SM (6, 18); however, the me-
chanisms involved in the apparent spontaneous resolution 
observed in approximately 70–80% of children has not 
been elucidated. Other pathogenic factors appear to be 
responsible for the final disease phenotype in adult as 
well as paediatric mastocytosis because the burden of 
clonal MCs and presence of KIT mutations alone does 
not explain the remarkable heterogeneity of the clinical 
presentation and prognosis of the disease. 
The complex physiology of the MC and its mediators is 
probably contributing to the varying clinical presentations 
and heterogeneous challenges in mastocytosis. The classic 
allergic immunoglobulin E (IgE)-mediated MC degranula-
tion is one of the best described cellular reactions; however, 
MC activation is often non-IgE-mediated and can be indu-
ced by several different IgE-independent triggers. Further-
more, MCs may release numerous preformed as well as de 
novo synthesized mediators, of which histamine is the best 
known. Another well-known mediator is tryptase. Elevated 
baseline serum tryptase is characteristically found in SM, 
although a normal serum tryptase level does not rule out 
the presence of mastocytosis (2, 16). In the follow-up and 
monitoring of patients with mastocytosis s-tryptase is a wi-
dely used marker of MC burden (19). Furthermore, a rapid 
event-related rise and subsequent decrease in s-tryptase is 
of value when diagnosing MC degranulation in anaphylaxis 
(20, 21). Another group of MC mediators contributing to 
complex symptomatology are prostaglandins, of which 
prostaglandin D2 is best described in mastocytosis, and 
may be targeted by the use of low-dose aspirin, even though 
aspirin/non-steroidal anti-inflammatory drugs (NSAIDs) 
may also cause exacerbations in intolerant patients (22–24).
DIAGNOSTIC CRITERIA AND WORK-UP
Mastocytosis may come to clinical attention in several 
ways and be suspected as differential diagnosis to many 
conditions (Fig.1). Common clinical presentations 
include a spectrum ranging from gradually appearing 
typical skin lesions, allergic symptoms including 
anaphylaxis (e.g. after bee or wasp stings), unex-
plained gastrointestinal (GI) symptoms, headache, 
hypotension, neuropsychiatric symptoms, rheumatic 
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symptoms/bone pain, osteoporotic fracture, to fati-
gue, cytopaenia, ascites and weight loss in advanced 
disease subtypes. Recognizing mastocytosis may be 
a challenge and diagnosis is often delayed due to 
lack of awareness among healthcare professionals. 
In all adult patients and all childhood patients, a precise 
and complete physical examination is standard. 
In paediatric mastocytosis the, by far, most common 
presenting symptom is the appearance of multiple skin 
lesions or a mastocytoma (25). In children the diag-
nosis of CM is largely clinical and a BM examination 
is not warranted or recommended except for the very 
rare situation where the child does not thrive and, in 
addition, shows persistently high and rising s-tryptase 
levels, abnormal blood count, or hepato-/splenomegaly. 
Given the many clinical features and symptoms in adult 
mastocytosis that have to be recognized and handled by 
different specialists, a step-wise approach for initial work-
up in adults with suspected mastocytosis is recommended 
(Fig. 2). The first step is a thorough skin examination for 
typical skin lesions, which may be inconspicuous and 
preferably should be confirmed by skin biopsy, especially 
in atypical cases. It is recommended that histological 
examination of skin biopsies should include staining for 
tryptase in addition to routine Giemsa and H&E stains, 
whereas CD25 and CD2 often is negative (26). If skin 
lesions are present the provisional diagnosis of MIS is 
established with recognition (and patient information) that 
this condition is a very strong indicator of the presence 
of SM in adults. In this situation, it is recommended to 
refer the patient for work-up in centres with experience 
in mastocytosis. In general, these centres recommend and 
perform a thorough BM examination in order to exclude 
or to establish the diagnosis of SM, to assess the BM MC 
burden, and to rule out or demonstrate the presence of 
another (associated) haematological disease. 
If skin lesions are not present, but s-tryptase levels are 
elevated and/or other signs and symptoms would argue 
for the presence of SM, it is recommended to perform 
a sensitive KIT D816V mutation analysis in the PB. If 
the KIT D816V mutation is detected a referral to a mas-
tocytosis centre is recommended for work-up for SM 
regardless of s-tryptase level. If the mutation analysis 
is negative a further work-up for mastocytosis is war-
ranted only if patient history and symptoms are highly 
indicative of mastocytosis and/or baseline s-tryptase is 
persistently above 20–30 ng/ml or continuously rising. 
If this is not the case, mastocytosis is unlikely and 
may, in practice, be ruled out. Of note, s-tryptase is not 
disease-specific for mastocytosis and may be elevated 
in healthy individuals, and in other conditions, such 
as chronic urticaria, kidney failure, chronic helminth 
infections, or other myeloid haematological diseases. 
A similar, step-wise approach, including KIT D816V 
testing in the algorithm is recommended by the ECNM 
(27).
The prerequisite for using this approach is the availa-
bility of a highly sensitive KIT D816V mutation analysis, 
since KIT D816V allele burden may be very low in ISM, 
often less than 0.01%, and hence there is a great risk of 
false-negative results if a less sensitive method is applied.
On the other hand, use of such a sensitive method 
may identify patients with SM among, for example, ana-
phylaxis patients not otherwise diagnosed due to absent 
skin lesions, lack of other MC mediator symptoms and 
normal baseline s-tryptase (28).
Diagnostic criteria for SM according to the WHO are 
listed in Table III. The diagnosis of SM requires investi-
gation of an extracutaneous organ (tissue of choice: BM) 
and can be made when the major and at least one minor 
criterion or 3 minor criteria are found (3, 4).
The BM examination (with complete pathological 
work-up) in mastocytosis is challenging for the non-
experienced pathologist. Therefore, it is recommended 
that the BM is examined by a pathologist with experience 
in diagnosing SM. Histopathological findings in BM sec-
tions in SM may be subtle and easily overlooked. Staining 
should include tryptase, CD117 and CD25, as well as 
CD30 if available, in addition to routine Giemsa and HE 
stains. Aberrant expression of CD2, CD25, and CD30 in 
neoplastic MCs can also be detected by flow cytometry, 
but this requires expertise. As part of the pathological 
evaluation the BM has to be evaluated thoroughly for 
the presence of an AHNMD, fibrosis, signs of ASM and 
signs of MCL. In a first step, a good-quality BM smear 
(or a touch preparation) needs to be investigated using 
Wright-Giemsa or May-Grünwald-Giemsa stain. In this 
investigation the most critical parameters are the percen-
Typical skin lesions? 
KIT D816V in blood? 
Typical other signs of SM present*? 
Follow up:   
continuously rising s-tryptase? 
and/or need for exclusion of SM** 
No 
No 
No 
No 
Yes 
Yes 
Yes 
Yes 
Mastocytosis unlikely 
Work-up for SM
Suspected mastocytosis – adults
(anaphylaxis, elevated, s-tryptase,
mediator related symptoms)
Fig. 2. Diagnostic algorithm presently used at Mastocytosis Centre Odense 
University Hospital and Oslo University Hospital. *Recurring spontaneous 
anaphylaxis, early osteoporosis, mast cell mediator related symptoms, 
GI symptoms, flushing **Haematological abnormalities, differential 
diagnostic purposes.
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tage of MCs, the morphological grading of MCs, and the 
investigation of all other myeloid lineages, especially with 
regard to dysplasia, blast cell counts, and other signs of an 
AHNMD. In addition, chromosome analysis is standard; 
and in case of a suspected AHNMD, additional fluore-
scence in situ hybridization studies should be performed.
In adults diagnosed with SM further clinical work-up 
needs to be performed. In general, it is recommended 
that all adults are examined with a dual-energy X-ray 
absorptiometry (DXA) scan (see below) to exclude or 
confirm osteopaenia or osteoporosis. Furthermore, it is 
standard to perform a routine chest X-ray and ultrasound 
of the abdomen in order to define the spleen size and to 
exclude or demonstrate the presence of lymphadenopathy. 
A thorough allergological work-up in case of anaphylaxis 
is important. Depending on symptoms and findings in 
the individual patient, further work-up may include GI 
endoscopy and imaging, radiological bone examinations, 
neuropsychological evaluation and other investigations 
relevant for ruling out differential diagnoses.
CLINICAL MANIFESTATIONS AND TREATMENT 
OPTIONS
General considerations
In general, patients with mastocytosis are best handled 
by centres with experience in managing the disease, 
using a coordinated, multidisciplinary approach and it 
is advised that patients with mastocytosis are referred 
to such a centre for evaluation, if possible. 
Treatment and follow-up should be focused on the in-
dividual patient, and tailored to patient’s symptoms, di-
sease manifestations, and the clinical course. Treatment 
options can be divided into anti-mediator therapy, aimed 
at reducing release or effects of MC mediators, and 
cytoreductive therapies aimed at reducing MC burden. 
Due to potential side-effects of currently available drugs, 
and given the normal life expectancy in ISM and CM, 
the latter should be reserved for the few patients with 
advanced SM or ISM with high MC burden and severe 
treatment-resistant symptoms. A thorough provision of 
patient information and counselling is standard. Most 
patients seek information through the Internet, but this 
may vary in quality and relevance and thus may lead to 
misinformation and unnecessary concerns. The ECNM 
homepage provides updated information to patients and 
doctors, as well as list of centres of excellence and of 
reference centres in most European countries. 
Identifying and avoiding relevant triggers of MC 
degranulation is of importance in all patients. Although 
some triggers are commonly reported (e.g. heat, insect 
stings, alcohol, friction, spicy foods), general advice to 
avoid a long list of theoretical triggers is not helpful, 
but must be individualized and related to the patient’s 
experience. Patients should, however, be informed about 
potential risk situations (e.g. wasp sting, contrast media, 
general anaesthesia), and it is advisable to provide writ-
ten information to the patient and involved healthcare 
personnel.
Most centres advise that all adults with mastocytosis 
and children with severe disease are equipped with an 
adrenaline auto-injector for use in case of anaphylaxis 
(see below), although firm evidence supporting this 
approach in clinical trials is lacking. 
Skin manifestations
The most common presenting symptom in mastocytosis, 
especially in children, is the gradual onset of pigmented, 
reddish-brown, maculopapular well-demarcated skin 
lesions traditionally named urticaria pigmentosa (UP) 
(Fig. 3). However, although the term UP is still widely 
used, the more correct term for skin lesions in adult 
mastocytosis is MIS, as explained above. In children 
and in adult cases where SM has been ruled out, skin 
lesions are termed maculopapular CM (MPCM) (3). 
The number of skin lesions may vary from very few 
(<5), easily missed in routine clinical examination, 
to widespread skin involvement covering most of the 
skin. In adults skin lesions are typically monomorphic 
and small-sized (up to 5 mm in diameter), whereas 
lesions are often larger and more polymorphic in pae-
diatric mastocytosis (26). Skin lesions typically show 
a wheal-and-flare reaction upon rubbing or stroking; 
so-called Darier’s sign (Fig. 4). In daily clinical prac-
tice a useful approach to elicit this sign is applying 5 
strokes with a tongue spatula with a moderate pressure 
Table III. WHO diagnostic criteria for systemic mastocytosis
Major criterion
Multifocal, dense infiltrates of mast cells (15 or more mast cells in aggregates) detected in sections of bone marrow and/or other extracutaneous organ(s), 
and confirmed by tryptase immunohistochemistry or other special stains
Minor criteria
a. In biopsy sections of bone marrow or other extracutaneous organs, more than 25% of the mast cells in the infiltrate are spindle-shaped or have atypical 
morphology or, of all mast cells in bone marrow aspirate smears, more than 25% are immature or atypical mast cells 
b. Detection of KIT point mutation at codon 816 in bone marrow, blood or other extracutaneous organ(s) 
c. Mast cells in bone marrow, blood or other extracutaneous organs that co-express CD117 with CD2 and/or CD25 
d. Serum total tryptase persistently >20 ng/ml* 
A diagnosis of systemic mastocytosis can be made if the major and one minor criterion or minimum 3 minor criteria are present. *Criterion not valid if there 
is an associated clonal myeloid disorder. From Horny et al. (4).
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over the skin lesions, and waiting 3–5 min (up to 15 
min) to evaluate response. False-negative results are 
sometimes encountered due to intake of antihistamines 
and individual thresholds. Dermographism (stripes of 
whealing in the normal skin upon scratching) may be 
seen in mastocytosis, but is also a common finding in 
some types of urticaria, and should not be confused 
with Darier’s sign.
The presence of telangiectasia, along with MPCM-like 
skin lesions, has traditionally been termed telangiectasia 
macularis eruptiva perstans (TMEP). There is, however, 
no clear evidence that this is a separate subtype of CM, or 
whether it merely represents a well-vascularized MPCM 
with dilated vessels in the skin. Therefore, even though 
telangiectasia may sometimes be a predominant clinical 
feature, the term TMEP should no longer be used (26).
In children the skin lesions are often clinically larger 
(Fig. 5) and polymorphic. Other subtypes include mas-
tocytoma of the skin and diffuse cutaneous mastocytosis 
(DCM) (see below).
Skin symptoms include pruritus, flushing and whea-
ling, often triggered by physical stimuli such as heat, 
cold, sunlight, and friction. These MC mediator-related 
skin symptoms can often be controlled by the use of H1-
anthistamines that may be administered in increasing 
doses and up to 4 times daily in line with treatment 
principles in chronic urticaria.
Cosmetic complaints are a major issue in many pa-
tients, especially in younger adults, and should not be 
underestimated. The challenge of treating the skin le-
sions is, however, that they are caused by MC infiltration 
in the skin, rather than MC mediators, and hence require 
reduction in this infiltration. Indeed, the disappearance 
of skin lesions has been reported after the use of cy-
toreductive therapies, such as cladribine and tyrosine 
kinase inhibitors, in patients with ASM. However, use 
of potentially toxic drugs in ISM or CM is not warranted 
for cosmetic indications. Therefore, current studies aim 
at identifying KIT-targeting tyrosine kinase inhibitors 
that are less toxic and can be applied safely in these 
patients. At present, however, treatment targeting the 
cosmetic burden of skin lesions is limited to ultraviolet 
(UV) therapy and short-term high-potency topical ste-
roids under plastic occlusion, alone or in combination. 
These treatments should be used with caution due to 
potential cutaneous side-effects, but may, in addition 
to reducing MC mediator skin symptoms, also make 
Fig. 5. Maculopapular cutaneous mastocytosis (MPCM) in a child with 
larger, reddish-brown lesions of different sizes over the trunk.
Fig. 3. Typical mastocytosis skin findings in an adult patient with 
symmetrically distributed, small, partly confluent, macular, brown, 
monomorphic lesions, traditionally termed urticaria pigmentosa, on the 
trunk and arms.
Fig. 4. Darier’s sign is an important dermatological finding and may be 
elicited by stroking a mastocytosis skin lesion approximately 5 times with 
moderate pressure with a tongue spatula. Within a few minutes, a wheal 
and flare reaction of the lesion develops (arrow).
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skin lesions somewhat less visible, although the effect 
is temporary. A few reports exist on the effects of laser 
treatment for skin lesions, e.g. on the face; however, 
experience is limited. 
Anaphylaxis
The prevalence of anaphylaxis in the general population 
has been estimated to be 0.05–2%, whereas reported 
prevalence in adults with mastocytosis is 35–50% and 
5–10% in children with this disease. Common elici-
tors include Hymenoptera sting (approximately 50%), 
drugs including opioids, contrast media, NSAIDs and 
muscle relaxants, whereas more infrequent triggers are 
IgE-mediated allergies to foods, antibiotics and latex 
(29). More general triggers, such as physical stress, 
exercise, fever, alcohol, cold/heat and spicy foods, are 
not common causes of severe anaphylaxis by isolated 
exposure, but may act in combination. Other triggers 
may be relevant in the individual patient, and each 
patient with mastocytosis should be advised to record 
all events and to learn (as far as possible) what triggers 
are harmful, in order to avoid these. In approximately 
one-third of anaphylaxis patients with mastocytosis 
no obvious cause can be identified even after thorough 
evaluation, so-called idiopathic anaphylaxis, probably 
reflecting a spontaneous MC activation (29, 30). 
In general, the incidence of IgE-mediated allergic 
rhinitis, asthma and food allergies is not more frequent 
in mastocytosis, but symptoms may be more severe and 
difficult to control when the conditions co-exist. 
No firm predictors or surrogate markers have been 
identified to allow an individual risk assessment for 
anaphylaxis in mastocytosis and further studies are 
needed. In paediatric mastocytosis the risk may be cor-
related with the severity and character of skin lesions 
as well as the level of s-tryptase. In contrast, risk of 
anaphylaxis in adults does not correlate with MC bur-
den or may even correlate inversely, and adult patients 
without skin lesions (BMM) may even be more prone 
to anaphylaxis than patients with typical ISM. In addi-
tion, patients with ASM and MCL may paradoxically 
lack MC mediator-related symptoms. 
Presently, even though firm evidence is lacking, 
most centres recommend that all adults with masto-
cytosis are equipped with an adrenaline auto-injector 
for use in case of anaphylaxis, whereas in paediatric 
mastocytosis only children with very extensive skin 
involvement, bullous skin reactions, persistently high 
tryptase levels (> 100), or previous anaphylaxis need to 
be prescribed an adrenaline pen. In addition, patients 
should be informed about potential MC triggers and risk 
situations, as described above, and a thorough evalua-
tion and allergological work-up is recommended in case 
of anaphylaxis. Patients with bee/wasp (Hymenoptera) 
allergy may be offered venom immunotherapy (VIT) 
that must be continued life-long. Due to risk of severe 
side-effects of venom injections it is advised that VIT in 
mastocytosis is performed by specialized allergy centres 
with experience in mastocytosis. 
Gastrointestinal symptoms
GI symptoms, including abdominal pain, cramping, 
diarrhoea and peptic symptoms are frequently encoun-
tered in SM (29, 31). Symptoms may be severe and/or 
have overlap with symptoms of other GI diseases (gast-
roesophageal reflux, Helibacter pylori associated GI 
ulcers, irritable bowel syndrome, inflammatory bowel 
diseases, coeliac disease, malignant disease). Therefore, 
these patients must be evaluated to rule out these diffe-
rential diagnoses. The pathogenesis of GI symptoms in 
mastocytosis involves the accumulation of clonal MCs 
in the GI tract, as well as MC mediator release, which 
may be triggered by various stimuli, e.g. spicy foods, 
alcohol, stress, or even occur spontaneously. Histology 
of GI biopsies may exhibit infiltrates of neoplastic MCs; 
however, changes can be focal and subtle, making re-
cognition challenging, especially compared with normal 
GI mucosa (32). Reported, characteristic endoscopic 
findings in GI-mastocytosis include mucosal erythema, 
granularity or nodularity; however, approximately half 
of affected patients do not show endoscopic abnorma-
lities in spite of histological changes and it is advisable 
to take multiple random biopsies at different sites in 
addition to visibly abnormal areas (31–35). Treatment 
options include H2 blockers, proton-pump inhibitors 
and oral sodium cromolyn that may be combined. In-
dividual triggers for symptoms should be identified by 
case history and avoided if possible. In a minor subset 
of patients a true IgE-mediated food allergy may be 
suspected needing specialized allergological work-up. 
In the rare aggressive subtypes of SM, malabsorption 
and weight loss may occur due to severe MCs infiltration 
in the GI tract. In this situation cytoreductive therapy 
may be warranted (36, 37).
Bone/osteoporosis 
Within all subcategories of SM, more than half of patients 
show skeletal involvement, including not only osteopo-
rosis and osteolytic lesions, but also osteosclerosis (38, 
39). Osteopaenia and osteoporosis are the most frequent 
and important bone complications of SM. Approximately 
30% of adult patients with SM have osteoporosis, which 
may go undetected due to lack of symptoms (40). The 
pathogenesis involved has not been fully elucidated but 
may involve MC-derived cytokines, receptor activator 
of nuclear factor kappa-B ligand (RANKL), as well as 
effects of MC mediators (proteolytic enzymes and hepa-
rin) on bone metabolism and remodelling (41, 42). Onset 
may be early in life and no clear predictors have been 
identified, thus it is advised to screen all adult patients 
with SM by DXA. Further work-up and radiological 
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examinations, including total spine radiography, depend 
on individual clinical presentation, including the presence 
of focal skeletal symptoms. Patients with severe, atypical 
or progressive osteoporosis and young individuals should 
be referred to a specialist in osteoporosis for evaluation. 
Clinical trials on specific treatments in SM-associated 
osteoporosis are lacking. Therefore, at present it is advi-
sed to follow general guidelines for osteopaenia and oste-
oporosis concerning treatment and follow-up, including 
vitamin D and calcium supplements and bisphosphonates 
(39). Early institution of bisphosphonates, as soon as the 
T-score on DXA is below –2, has been suggested in a 
previous consensus document (2). The effectiveness of 
new drugs, such as denosumab, remains to be determined. 
Based on our limited understanding of the pathogenic 
mechanisms underlying the development and evolution 
of osteoporosis in SM, no more specific treatment or 
prophylaxis can be recommended presently. It is probable 
that MC mediators are involved and therefore it may be 
hypothesized that an effective anti-mediator treatment 
may prevent development of osteoporosis; however, evi-
dence supporting this approach is lacking. On the other 
hand, it appears that MC burden does not correlate with 
increased frequency of osteoporosis and cytoreductive 
treatments are generally not warranted for this indication 
(43, 44). It must be stressed that the presence of an osteo-
porotic fracture is not a sign of aggressive disease, i.e. 
a C-finding, as opposed to the rarely encountered large, 
osteolytic bone lesions that can sometimes be detected 
in patients with ASM or MCL (2). 
Musculoskeletal involvement
Poorly localized pain from soft tissue and bone is a 
frequent complication of SM and probably related to ef-
fects of MC mediators including prostaglandins, but the 
pathogenic mechanism is not well understood (24, 44, 
45). Laboratory tests, radiological imaging and referral to 
a rheumatologist may be relevant to rule out differential 
diagnoses. Therapeutic options include conventional anal-
gesics, NSAIDs/aspirin if tolerated, physiotherapy and 
exercise. Furthermore, blocking MC mediators may aid 
in gaining control of symptoms (46, 47). Opioids should, 
in general, be avoided given the chronicity of SM, and 
due to side-effects including potential MC triggering.
Neuropsychiatric symptoms
Neuropsychiatric symptoms are frequently encountered 
in mastocytosis and include headache, depression, anx-
iety, and cognitive impairment and memory problems 
(48–52). It is estimated that these types of symptoms 
affect approximately one-third of patients with SM and 
may sometimes be severe (44). The mechanism is not 
clear, but may involve the effect of MC mediators in 
the central nervous system. Other factors, such as dif-
ficulty coping with a chronic disease such as mastocy-
tosis, may also play a role. These symptoms may have 
a severe impact on daily life in many SM patients and 
therefore deserve recognition. As is the case for many 
of the manifestations of mastocytosis a thorough search 
for differential diagnoses is important and includes a 
psychiatric and/or neurological work-up, depending 
on the type and severity of symptoms. Treatment 
options comprise blocking of MC mediators by H1-
antihistamines, leukotriene antagonists, antidepressants 
and psychological support. Other potentially useful 
drugs could include sodium cromolyn and omalizumab 
(53–55); however, studies on this manifestation of SM 
and treatment options are required. 
ADVANCED FORMS OF SYSTEMIC MASTO-
CYTOSIS
Aggressive systemic mastocytosis (ASM) is characte-
rized by organ dysfunction due to MC infiltration. The 
diagnosis of ASM requires the presence of at least one 
C-finding (Table III) related to a documented local MC 
infiltration. Thus, biopsies from, for example, liver or 
spleen may be required to document the causal rela-
tionship with a malignant MC-infiltrate and thus the 
presence of a C-finding. Anaemia, thrombocytopenia, 
neutropaenia, ascites, hypoalbuminaemia, and conside-
rable weight loss are frequently present in patients with 
ASM. Large osteolysis with and without pathological 
fractures may also be detected.
In ASM cytoreductive treatment is needed in order 
to reduce the MC burden and restore organ function, 
whereas MC mediator-related symptoms often play a 
minor role. Usually, the slowly progressing form of 
ASM can be kept under control with interferon-α or 
chlorodeoxyadenosine (cladribine) for months or even 
years (56). If these treatments fail, PKC412 (midostau-
rin), an oral multi-kinase inhibitor blocking wild-type 
as well as mutated KIT, should be considered, as it has 
been demonstrated that this drug can induce clinically 
meaningful responses in most patients with ASM. In 
addition, PKC412 has been described to have an effect 
on overall survival in patients with ASM and MCL (57). 
The tyrosine kinase inhibitors nilotinib and dasatinib, 
which are inhibitors of mutated KIT, have shown only 
minor clinical effects, whereas imatinib has no thera-
peutic role in the presence of the KIT D816V mutation, 
but only in patients without this mutation (9). In patients 
with rapidly progressing ASM, ASM in transformation 
to MCL (ASM-t), or overt MCL, more intensive therapy 
is usually required. However, MCL can be divided into 
acute and chronic forms. In acute MCL cladribine or 
PKC412 have only limited effect, whereas patients with 
the less aggressive chronic MCL have a longer survi-
val when treated with cladribine or midostaurin (12). 
In younger patients with a suitable donor, allogeneic 
stem cell transplantation (SCT) is the only treatment 
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with a chance of inducing stable remission in patients 
with rapidly progressing ASM or acute MCL (9, 58). In 
these patients, polychemotherapy (as otherwise given to 
patients with high-risk AML) is initially administered. 
One standard protocol is fludarabine, cytarabine and 
granulocyte colony-stimulating factor (FLAG). In those 
who show a good response, 2–3 cycles are given, and 
the patient is then prepared for SCT. 
In SM-AHNMD treatment should be guided by both 
the ASM component and the non-MC neoplasm. In 
those with ASM-AHNMD, treatment often needs to 
be adjusted to the ASM-component of the disease. By 
contrast, in those with ISM-AHNMD, the cytoreductive 
therapy follows the guidelines for treating the AHNMD 
type (as if no SM had been diagnosed). 
SPECIAL ASPECTS
Paediatric mastocytosis
The most common clinical scenario leading to diagnosis 
of mastocytosis in the paediatric population is a child 
presenting with skin lesions within the first 2 years of 
life. Symptoms in paediatric mastocytosis are usually 
mild to moderate and are often limited to the skin (25, 
59, 60). It is, however, recommended that children with 
mastocytosis are offered an evaluation by experienced 
mastocytosis centres with established collaboration with 
paediatricians. 
An as-yet unsolved enigma is the spontaneous resolu-
tion observed in the majority of children as described 
above (5). One possible explanation is differences 
in mutational profiles compared with adults. In the 
paediatric population it is only possible to detect the 
KIT D816V mutation in approximately 25–35%, while 
80–95% of adult patients with typical ISM carry this 
mutation (6). Apparently non-D816V KIT mutations 
are more frequent in children (18).
The clinical character of skin lesions in paediatric 
mastocytosis is more heterogeneous than in adults. Some 
children exhibit classic, small monomorphic UP-skin le-
sions like adults, whereas others have larger, polymorphic 
lesions (61) (Fig. 5). Recent data have suggested that 
children presenting with monomorphic small-sized le-
sions have a higher risk of having persistent mastocytosis, 
whereas in those with polymorphic larger lesions, the 
disease more often resolves before or at puberty (26, 62).
A rare paediatric subtype is diffuse cutaneous mas-
tocytosis (DCM) in which the whole integument is 
infiltrated by MCs. Children with DCM do not present 
with individual lesions, but rather exhibit generalized 
erythema, usually with thickened, darker skin and a 
very pronounced dermographism with often bullous 
reactions. The clinical presentation of DCM may be 
dramatic, with extensive blistering and hypotensive 
episodes; however, improvement is usually seen within 
the first 3–4 years. Although tryptase levels are often 
increased at presentation, evidence of systemic invol-
vement is usually not found and spontaneous regression 
over time is the rule (26, 63).
Another type of CM almost exclusively seen in the 
paediatric population is mastocytoma of the skin, often 
presented in clinic by worried parents as an itchy and 
swollen naevus. Even though the vast majority of pa-
tients have very limited symptoms that do not require 
treatment, occasionally these may be accompanied by 
generalized flushing and hypotensive episodes, i.e. 
anaphylaxis, for which excision may be considered (25). 
Symptomatic treatment options include H1-anthistami-
nes, topical or intralesional steroids. 
A diagnosis of CM and not SM is presumed in all 
children with typical MPCM-skin lesions and a BM 
examination is not recommended except for the very 
rare situation where the child does not thrive, and in 
addition shows persistently high and rising s-tryptase, 
abnormal blood counts, or hepato/splenomegaly. A 
follow-up is recommended, and if the disease persists 
into adulthood a work-up as described for adults, in-
cluding a BM examination, should be performed (2). 
Aggressive subtypes of mastocytosis are exceedingly 
rare in the paediatric population.
At present no firm predictors for persistent disease ex-
ist. From a biological angle it is tempting to assume that 
children carrying the KIT D816V mutation will persist 
into adult mastocytosis. However, long-term prospective 
studies have not been performed, and there are children 
with KIT D816V-positive skin lesions in whom these 
lesions disappear during puberty. Similarly, disease on-
set after 3 years of age may be predictive of persisting 
disease. Finally, the clinical appearance of small mono-
morphic UP-skin lesions, i.e. skin lesions like those found 
in adults, are an assumed clinical predictor for persistence 
in patients with childhood mastocytosis (62).
Treatment should be aimed at symptoms and is not 
always needed. Information about common triggers for 
MC activation, such as friction, heat and cold, should 
be given, but should be individualized and, apart from 
physical stimuli to the skin, most other theoretical triggers 
do not have clinical relevance in childhood mastocytosis 
and it must be stressed that it is not helpful to provide a 
long list of potential MC triggers to avoid. To that end, 
counselling and thorough information for often worried 
parents is of great help, bearing in mind that information 
found on the Internet on this very heterogeneous disease 
may vary greatly in relevance and quality and can thereby 
lead to misinformation and unnecessary concerns.
Antihistamines in general suffice to control skin 
symptoms. Non-sedating H1-antihistamines should be 
prescribed. Short periods of sedating antihistamines may 
be warranted for sleep-disturbing symptoms, but should 
not be prescribed for long-term use. Topical steroids may 
dampen skin symptoms and increase the threshold for MC 
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activation, but should be prescribed only for short-term 
use due to potential side-effects in the skin (25).
Risk of anaphylaxis in paediatric mastocytosis is much 
lower than in adult mastocytosis, and presently it is only 
warranted to prescribe an adrenaline pen as emergency 
medication for children with very extensive skin invol-
vement, bullous skin reactions, persistently high tryptase 
levels (>100) or previous anaphylaxis (64–66).
ANAESTHESIA 
The incidence of perioperative anaphylaxis in patients 
with mastocytosis is not known. However, it is generally 
assumed that the perioperative setting is a high-risk en-
vironment for mastocytosis patients due to the combina-
tion of multiple drug administrations and exposure to po-
tential triggers of mast degranulation, such as emotional 
stress, cooling/heating and pressure from tourniquets. 
Such assumptions have led to generalizations regarding 
drug groups to avoid when performing general anaesthe-
sia in mastocytosis patients, which in some cases have 
led to suboptimal care, i.e. with regard to management 
of postoperative pain. There is very limited literature 
on the subject and most recommendations are therefore 
based on the lowest level of evidence, such as informa-
tion from case reports combined with expert opinion. 
Individual reports of reactions in patients with mastocy-
tosis largely implicate drugs such as opioids, NSAIDs, 
antibiotics, radio-contrast media, local anaesthetics and 
muscle relaxants reflecting drugs commonly used and 
also implicated in perioperative anaphylaxis in non-
mastocytosis patients. Reports are presenting conflicting 
information, and affirmative evidence for avoidance of 
specific drugs is therefore lacking.
There are no studies of adult patients and, to date, very 
few studies of the perioperative management of paedia-
tric mastocytosis patients have been published. These 
point in the direction that, overall, anaesthesia is safe in 
the majority of paediatric mastocytosis patients without 
imposing generalized restrictions or precautions (67, 68).
Although the general risk of anaphylaxis in adult 
mastocytosis patients is greater than in children, it is 
still considered to be low in the majority of patients. 
Therefore, an individualized risk assessment should be 
carried out before surgery and anaesthesia in both adults 
and children with mastocytosis. 
Patients without previous episodes of anaphylaxis, 
perioperatively or to drugs, require no special precau-
tions other than continuing usual anti-mediator therapy. 
Patients with previous episodes of drug allergy should 
avoid specific drugs suspected of eliciting reactions. If 
previous reactions occurred perioperatively specialized 
allergological investigations, taking into account all 
perioperative exposures including anaesthetic drugs, 
latex, disinfectants, dyes, and antibiotics, should be 
carried out to try to identify the eliciting drug.
Procedures performed in regional (epidural/spinal), 
topical or local anaesthesia are generally considered safe 
(69–71) and precautions are warranted only in patients 
with a prior reaction.
In general, it is advised that mastocytosis patients in-
form the anaesthesiologist and the surgeon in good time 
preoperatively, to allow information to be gathered from 
previous anaesthesia records, so that previously tolerated 
anaesthesia regimens can be re-used. Detailed planning 
of the anaesthetic and the management of postoperative 
pain may be useful to avoid confusion and discussions 
about which drugs may be used on the day of surgery.
Some centres advocate a baseline s-tryptase prior to 
surgery so it is ready for comparison if a perioperative 
reaction occurs and s-tryptase is sampled at the time of 
reaction (68).
The use of premedication is not evidence-based, and 
no clear consensus exists, but is widely practiced. The 
patient’s regular anti-mediator therapy should be con-
tinued on the day of surgery and may be supplemented 
with premedication with a combination of antihistami-
nes (H1 and H2 antagonists) and glucocorticoids (72).
For all mastocytosis patients attention should be paid 
to reducing/avoiding triggers, such as emotional stress, 
excessive cooling/heating, pain, friction, prolonged 
pressure from tourniquets and other mechanical factors. 
Premedication with benzodiazepines is advocated in 
some centres to reduce anxiety and emotional stress.
When anaesthetizing a patient with mastocytosis 
the anaesthesiologist should be alert for early signs 
of anaphylaxis, such as flushing and urticaria (which 
may also be absent or not easily noticed), hypotension, 
tachycardia and bronchospasm and be prepared to treat 
life-threatening symptoms with adrenaline according to 
international guidelines.
VENOM IMMUNOTHERAPY
Patients with IgE-mediated anaphylaxis to Hymenop-
tera should be offered venom immunotherapy (VIT) to 
honeybee or wasp or both (73). This treatment reduces 
the risk of life-threatening anaphylactic episodes and 
should be performed life-long in patients with mastocy-
tosis. VIT in mastocytosis patients should be performed 
by experienced allergy centres due to the risk of severe 
side-effects, including anaphylaxis, and the need for 
dosage adjustments and concomitant treatments. 
PREGNANCY
In general, pregnancy in mastocytosis is uncomplicated 
as long as physicians are aware of the presence of the 
underlying disease. Approximately 25–33% of patients 
experience some worsening of their mediator-related 
symptoms during pregnancy, whereas 10–25% of pa-
tients experience some relief of their mediator-related 
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symptoms (74). Labour and delivery is, in general, 
uncomplicated without maternal or foetal complications 
and, overall, there is no need for special precautions/
observations (see anaesthesia above). Anti-mediator 
treatment of safe type, such as cetirizine or fexofena-
dine in normal dosages, should be continued during 
pregnancy and labour (75).
The authors declare no conflicts of interest.
Contact information for Nordic mastocytosis centres can be 
found at: www.mastocytose.dk.
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